Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more
Release Date:
Editor’s Summary by Preeti Malani, MD, MSJ, Deputy Editor of JAMA, the Journal of the American Medical Association, for the June 4, 2024, issue.
Ponatinib vs Imatinib for Ph+ ALL, Cholesterol from Childhood to Adulthood and CVD Risk, Causal Inference, and more